Roivant drug Mosliciguat meets Phase 2 goal; ROIV shares jump premarket
Roivant’s experimental lung disease drug Mosliciguat met the primary goal in a key Phase 2 study, driving ROIV shares up 22% in pre-market trading.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.